Aidence

Aidence is a Netherlands-based medical imaging company founded in Amsterdam in 2015. The company specializes in AI-powered solutions for the early detection and management of lung cancer. Its flagship product, Veye Lung Nodules, is an AI-based software that assists radiologists in detecting, classifying, quantifying, and monitoring pulmonary nodules in CT scans. This solution is widely utilized in clinical practice and lung cancer screening programs across Europe, enhancing diagnostic accuracy and improving patient outcomes. Aidence integrates its intelligent software into clinical workflows, ensuring continuous quality improvement and safety. The company collaborates with healthcare providers, including NHS England, and partners like AstraZeneca and Google Health to advance lung cancer diagnosis and screening. In 2023, Aidence was acquired by RadNet, positioning it to expand its presence in the US market and further develop AI applications in pulmonary nodule management. Aidence is committed to leveraging data to enhance disease prevention and treatment for lung cancer patients.

• Employees 18
• Founded 2015
• Annual Revenue $3000000
• Total Funding $13867640